Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics Q3 revenue up 12% to $134.2 million; raises revenue guidance

Positive Impact 4 of 5 earnings Written later

ADMA Biologics reported third quarter 2025 total revenue of $134.2 million, up 12% from a year earlier, and GAAP net income of $36.4 million, up from $35.9 million. The company raised its full-year 2025 revenue guidance to at least $510 million and its 2026 revenue guidance to at least $630 million, but lowered 2025 adjusted net income guidance to approximately $158 million from more than $175 million because of a higher effective tax rate.

Key points

  • Q3 2025 GAAP net income was $36.4 million versus $35.9 million in Q3 2024; adjusted EBITDA was $58.7 million, up 29%.
  • Gross margin was 56.3% versus 49.8% a year earlier.
  • FY 2025 revenue guidance raised to at least $510 million; FY 2025 adjusted net income revised to approximately $158 million from more than $175 million.
  • FY 2026 revenue guidance raised to at least $630 million; FY 2026 adjusted EBITDA guidance raised to more than $355 million.

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECNov 5, 2025, 4:11 PM ET
Accession number0001140361-25-040539

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.